Cargando…

Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review

BACKGROUND: In 2007, Canada chose to develop a separate and distinct path for oncology drug health technology assessment (HTA). In 2013, the decision was made to transfer the pan-Canadian Oncology Drug Review (pCODR) to the Canadian Agency for Drugs and Technologies in Health (CADTH), to align the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocchi, Angela, Chabot, Isabelle, Glennie, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461134/
https://www.ncbi.nlm.nih.gov/pubmed/26082654
http://dx.doi.org/10.2147/CEOR.S82549
_version_ 1782375487807422464
author Rocchi, Angela
Chabot, Isabelle
Glennie, Judith
author_facet Rocchi, Angela
Chabot, Isabelle
Glennie, Judith
author_sort Rocchi, Angela
collection PubMed
description BACKGROUND: In 2007, Canada chose to develop a separate and distinct path for oncology drug health technology assessment (HTA). In 2013, the decision was made to transfer the pan-Canadian Oncology Drug Review (pCODR) to the Canadian Agency for Drugs and Technologies in Health (CADTH), to align the pCODR and CADTH Common Drug Review processes while building on the best practices of both. The objective of this research was to conduct an examination of the best practices established by the pCODR. METHODS: A qualitative research approach was taken to assess the policies, processes, and practices of the pCODR, based on internationally accepted best practice “principles” in HTA, with a particular focus on stakeholder engagement. Publicly available information regarding the approach of the pCODR was used to gauge the agency’s performance against these principles. In addition, stakeholder observations and real-world experiences were gathered through key informant interviews to be inclusive of perspectives from patient advocacy groups, provincial and/or cancer agency decision-makers, community and academic oncologists, industry, expert committee members, and health economists. RESULTS: This analysis indicated that, through the pCODR, oncology stakeholders have had a voice in and have come to trust the quality and relevance of oncology HTA as a vital tool to ensure the best decisions for Canadians with cancer and their health care system. It could be expected that adoption of the principles and processes of the pCODR would bring a similar level of engagement and trust to other HTA organizations in Canada and elsewhere. CONCLUSION: The results of this research led to recommendations for improvement and potential extrapolation of these best practices to other HTA organizations worldwide, along with suggestions for continued evolution of the pCODR in conjunction with its integration into the CADTH. It is clear that the transition of the pCODR to CADTH provides an opportunity for practices initiated by the pCODR to become the standard for these newly amalgamated HTA agencies in Canada.
format Online
Article
Text
id pubmed-4461134
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44611342015-06-16 Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review Rocchi, Angela Chabot, Isabelle Glennie, Judith Clinicoecon Outcomes Res Original Research BACKGROUND: In 2007, Canada chose to develop a separate and distinct path for oncology drug health technology assessment (HTA). In 2013, the decision was made to transfer the pan-Canadian Oncology Drug Review (pCODR) to the Canadian Agency for Drugs and Technologies in Health (CADTH), to align the pCODR and CADTH Common Drug Review processes while building on the best practices of both. The objective of this research was to conduct an examination of the best practices established by the pCODR. METHODS: A qualitative research approach was taken to assess the policies, processes, and practices of the pCODR, based on internationally accepted best practice “principles” in HTA, with a particular focus on stakeholder engagement. Publicly available information regarding the approach of the pCODR was used to gauge the agency’s performance against these principles. In addition, stakeholder observations and real-world experiences were gathered through key informant interviews to be inclusive of perspectives from patient advocacy groups, provincial and/or cancer agency decision-makers, community and academic oncologists, industry, expert committee members, and health economists. RESULTS: This analysis indicated that, through the pCODR, oncology stakeholders have had a voice in and have come to trust the quality and relevance of oncology HTA as a vital tool to ensure the best decisions for Canadians with cancer and their health care system. It could be expected that adoption of the principles and processes of the pCODR would bring a similar level of engagement and trust to other HTA organizations in Canada and elsewhere. CONCLUSION: The results of this research led to recommendations for improvement and potential extrapolation of these best practices to other HTA organizations worldwide, along with suggestions for continued evolution of the pCODR in conjunction with its integration into the CADTH. It is clear that the transition of the pCODR to CADTH provides an opportunity for practices initiated by the pCODR to become the standard for these newly amalgamated HTA agencies in Canada. Dove Medical Press 2015-06-03 /pmc/articles/PMC4461134/ /pubmed/26082654 http://dx.doi.org/10.2147/CEOR.S82549 Text en © 2015 Rocchi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Rocchi, Angela
Chabot, Isabelle
Glennie, Judith
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
title Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
title_full Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
title_fullStr Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
title_full_unstemmed Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
title_short Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review
title_sort evolution of health technology assessment: best practices of the pan-canadian oncology drug review
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461134/
https://www.ncbi.nlm.nih.gov/pubmed/26082654
http://dx.doi.org/10.2147/CEOR.S82549
work_keys_str_mv AT rocchiangela evolutionofhealthtechnologyassessmentbestpracticesofthepancanadianoncologydrugreview
AT chabotisabelle evolutionofhealthtechnologyassessmentbestpracticesofthepancanadianoncologydrugreview
AT glenniejudith evolutionofhealthtechnologyassessmentbestpracticesofthepancanadianoncologydrugreview